Role of intestinal cytochrome P450 (P450) in modulating the bioavailability of oral lovastatin: Insights from studies on the intestinal epithelium-specific P450 reductase knockout mouse

Drug Metabolism and Disposition

Volumn 39, Issue 6, 2011, Pages 939-943

  Zhu, Yi ^a   D'Agostino, Jaime ^a   Zhang, Qing Yu ^a  

^a STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 REDUCTASE; MEVINOLIN; PRAVASTATIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; ENZYME ACTIVITY; EPITHELIUM CELL; FEMALE; FOOD DRUG INTERACTION; GRAPEFRUIT JUICE; INTESTINE CELL; INTESTINE EPITHELIUM; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ANIMALS; ANTICHOLESTEREMIC AGENTS; BEVERAGES; BIOLOGICAL AVAILABILITY; CITRUS PARADISI; FEMALE; FOOD-DRUG INTERACTIONS; INTESTINAL MUCOSA; INTESTINE, SMALL; LOVASTATIN; MICE; MICE, KNOCKOUT; NADPH-FERRIHEMOPROTEIN REDUCTASE;

CITRUS X PARADISI; MUS;

EID: 79956122356     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.037861     Document Type: Article

References (30)

1. Bailey DG, Malcolm J, Arnold O, and Spence JD (1998) Grapefruit juice-drug interactions. Br J Clin Pharmacol 46:101-110. (Pubitemid 28342779)
2. Chen C, Mireles RJ, Campbell SD, Lin J, Mills JB, Xu JJ, and Smolarek TA (2005) Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos 33:537-546. (Pubitemid 40393197)
3. Ding X and Kaminsky LS (2003) Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu Rev Pharmacol Toxicol 43:149-173. (Pubitemid 37372638)
4. Doherty MM and Charman WN (2002) The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism? Clin Pharmacokinet 41:235-253. (Pubitemid 34533755)
5. Duggan DE, Chen IW, Bayne WF, Halpin RA, Duncan CA, Schwartz MS, Stubbs RJ, and Vickers S (1989) The physiological disposition of lovastatin. Drug Metab Dispos 17:166-173. (Pubitemid 19083601)
6. Edwards DJ, Fitzsimmons ME, Schuetz EG, Yasuda K, Ducharme MP, Warbasse LH, Woster PM, Schuetz JD, and Watkins P (1999) 6′,7′- Dihydroxybergamottin in grapefruit juice and Seville orange juice: effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein. Clin Pharmacol Ther 65:237-244. (Pubitemid 29142929)
7. Fang C and Zhang QY (2010) The role of small-intestinal P450 enzymes in protection against systemic exposure of orally administered benzo[a]pyrene. J Pharmacol Exp Ther 334:156-163.
8. Fasco MJ, Silkworth JB, Dunbar DA, and Kaminsky LS (1993) Rat small intestinal cytochromes P450 probed by warfarin metabolism. Mol Pharmacol 43:226-233. (Pubitemid 23055066)
9. Honda Y, Ushigome F, Koyabu N, Morimoto S, Shoyama Y, Uchiumi T, Kuwano M, Ohtani H, and Sawada Y (2004) Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux. Br J Pharmacol 143:856-864. (Pubitemid 39664844)
10. Hsu I, Spinler SA, and Johnson NE (1995) Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Ann Pharmacother 29:743-759.
11. Ishigami M, Honda T, Takasaki W, Ikeda T, Komai T, Ito K, and Sugiyama Y (2001) A comparison of the effects of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro. Drug Metab Dispos 29:282-288. (Pubitemid 32179528)
12. Jacobsen W, Kirchner G, Hallensleben K, Mancinelli L, Deters M, Hackbarth I, Baner K, Benet LZ, Sewing KF, and Christians U (1999a) Small intestinal metabolism of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor lovastatin and comparison with pravastatin. J Pharmacol Exp Ther 291:131-139. (Pubitemid 29451582)
13. Jacobsen W, Kirchner G, Hallensleben K, Mancinelli L, Deters M, Hackbarth I, Benet LZ, Sewing KF, and Christians U (1999b) Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3- methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. Drug Metab Dispos 27:173-179. (Pubitemid 29072068)
14. Jain DS, Subbaiah G, Sanyal M, Jain VK, and Shrivastav P (2007) A rapid and specific approach for direct measurement of pravastatin concentration in plasma by LC-MS/MS employing solid-phase extraction. Biomed Chromatogr 21:67-78. (Pubitemid 46164993)
15. Kaminsky LS and Zhang QY (2003) The small intestine as a xenobiotic-metabolizing organ. Drug Metab Dispos 31:1520-1525. (Pubitemid 37466920)
16. Kantola T, Kivistö KT, and Neuvonen PJ (1998) Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 63:397-402. (Pubitemid 28214962)
17. Lin JH, Chiba M, and Baillie TA (1999) Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol Rev 51:135-158.
18. Lodge JW, Fletcher BL, Brown SS, Parham AJ, Fernando RA, and Collins BJ (2008) Determination of lovastatin hydroxy acid in female B6C3F1 mouse serum. J Anal Toxicol 32:248-252. (Pubitemid 351482107)
19. Mertens-Talcott SU, Zadezensky I, De Castro WV, Derendorf H, and Butterweck V (2006) Grapefruit-drug interactions: can interactions with drugs be avoided? J Clin Pharmacol 46:1390-1416. (Pubitemid 44704201)
20. Mulvana D, Jemal M, and Pulver SC (2000) Quantitative determination of pravastatin and its biotransformation products in human serum by turbo ion spray LC/MS/MS. J Pharm Biomed Anal 23:851-866.
21. Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, and Zeldin DC (2006) The human intestinal cytochrome P450 "pie." Drug Metab Dispos 34:880-886.
22. Schachter M (2005) Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 19:117-125.
23. Suzuki H and Sugiyama Y (2000) Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine. Eur J Pharm Sci 12:3-12.
24. Thummel KE, Kunze KL, and Shen DD (1997) Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. Adv Drug Deliv Rev 27:99-127. (Pubitemid 27417869)
25. van Herwaarden AE, Wagenaar E, van der Kruijssen CM, van Waterschoot RA, Smit JW, Song JY, van der Valk MA, van Tellingen O, van der Hoorn JW, Rosing H, et al. (2007) Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J Clin Invest 117:3583-3592. (Pubitemid 350097013)
26. Vyas KP, Kari PH, Pitzenberger SM, Halpin RA, Ramjit HG, Arison B, Murphy JS, Hoffman WF, Schwartz MS, and Ulm EH (1990) Biotransformation of lovastatin. I. Structure elucidation of in vitro and in vivo metabolites in the rat and mouse. Drug Metab Dispos 18:203-211. (Pubitemid 20107716)
27. Wang RW, Kari PH, Lu AY, Thomas PE, Guengerich FP, and Vyas KP (1991) Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. Arch Biochem Biophys 290:355-361.
28. Wu CY and Benet LZ (2005) Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 22:11-23.
29. Zhang QY, Dunbar D, and Kaminsky LS (2003) Characterization of mouse small intestinal cytochrome P450 expression. Drug Metab Dispos 31:1346-1351. (Pubitemid 37310323)
30. Zhang QY, Fang C, Zhang J, Dunbar D, Kaminsky L, and Ding X (2009) An intestinal epithelium-specific cytochrome P450 (P450) reductase-knockout mousemodel: direct evidence for a role of intestinal P450s in first-pass clearance of oral nifedipine. Drug Metab Dispos 37:651-657.